ITM's Clinical Trials for GEP-NET Patients
Two phase 3 clinical trials are undergoing to evaluate targeted radionuclide therapy with n.c.a. lutetium-177-edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).
COMPETE - Treatment Schedule
COMPOSE - Treatment Schedule
For more information, please check out www.itm-gep-net-trials.com